Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Seres Therapeutics (MCRB) Net Margin (2016 - 2023)

Seres Therapeutics (MCRB) has disclosed Net Margin for 8 consecutive years, with 5.17% as the latest value for Q4 2023.

  • Quarterly Net Margin rose 706117.0% to 5.17% in Q4 2023 from the year-ago period, while the trailing twelve-month figure was 4142.21% through Dec 2025, changed N/A year-over-year, with the annual reading at 3509.5% for FY2022, 346425.0% down from the prior year.
  • Net Margin hit 5.17% in Q4 2023 for Seres Therapeutics, up from 2206.13% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 480.66% in Q4 2020 to a low of 13634.87% in Q1 2023.
  • Historically, Net Margin has averaged 1979.9% across 5 years, with a median of 531.58% in 2020.
  • Biggest YoY gain for Net Margin was 706117bps in 2023; the steepest drop was -984223bps in 2023.
  • Year by year, Net Margin stood at 358.08% in 2019, then soared by 234bps to 480.66% in 2020, then plummeted by -244bps to 692.44% in 2021, then plummeted by -919bps to 7056.0% in 2022, then soared by 100bps to 5.17% in 2023.
  • Business Quant data shows Net Margin for MCRB at 5.17% in Q4 2023, 2206.13% in Q3 2023, and 36.81% in Q2 2023.